靶向药|当肿瘤也学会“百花齐放”，以精准著称的靶向药该如何破敌？( 四 )
[11].Fletcher J A. KIT oncogenic mutations: biologic insights, therapeutic advances, and future directions[J]. Cancer research, 2016, 76(21): 6140-6142.
[12].Oppelt P, Hirbe A C, Van Tine B A, et al. Gastrointestinal stromal tumors (GISTs): point mutations matter in management, a review[J]. Journal of gastrointestinal oncology, 2017, 8(3): 466-473.
[13].Antonescu C R. The GIST paradigm: lessons for other kinase‐driven cancers[J]. The Journal of Pathology, 2011, 223(2): 251-261.
[14].Corless C L, Schroeder A, Griffith D J, et al. PDGFRA Mutations in Gastrointestinal Stromal Tumors: Frequency, Spectrum and In Vitro Sensitivity to Imatinib[J]. Journal of Clinical Oncology, 2005, 23(23): 5357-5364.
[15].Desai J, Shankar S, Heinrich M C, et al. Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors[J]. Clinical Cancer Research, 2007, 13(18): 5398-5405.
[16].Heinrich M C, Corless C L, Blanke C D, et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors[J]. Journal of clinical oncology, 2006, 24(29): 4764-4774.
[17].Liegl B, Kepten I, Le C, et al. Heterogeneity of kinase inhibitor resistance mechanisms in GIST[J]. The Journal of Pathology: A Journal of the Pathological Society of Great Britain and Ireland, 2008, 216(1): 64-74.
[18].Wardelmann E, Merkelbach-Bruse S, Pauls K, et al. Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate[J]. Clinical Cancer Research, 2006, 12(6): 1743-1749.
[19].Serrano C, Mari?o-Enríquez A, Tao D L, et al. Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours[J]. British journal of cancer, 2019, 120(6): 612-620.
[20].Ding H, Yu X, Yu Y, et al. Clinical significance of the molecular heterogeneity of gastrointestinal stromal tumors and related research: A systematic review[J]. Oncology Reports, 2020, 43(3): 751-764.
[21].Liegl B, Kepten I, Le C, et al. Heterogeneity of kinase inhibitor resistance mechanisms in GIST. J Pathol. 2008;216(1):64-74.
[22].Naml?s HM, Boye K, Mishkin SJ, et al. Noninvasive Detection of ctDNA Reveals Intratumor Heterogeneity and Is Associated with Tumor Burden in Gastrointestinal Stromal Tumor. Mol Cancer Ther. 2018;17(11):2473-2480.
[23].Corless C L, Ballman K V, Antonescu C R, et al. Pathologic and Molecular Features Correlate With Long-Term Outcome After Adjuvant Therapy of Resected Primary GI Stromal Tumor: The ACOSOG Z9001 Trial[J]. Journal of Clinical Oncology, 2014, 32(15): 1563-1570.
[24].Heinrich M, Maki R G, Corless C L, et al. Primary and Secondary Kinase Genotypes Correlate With the Biological and Clinical Activity of Sunitinib in Imatinib-Resistant Gastrointestinal Stromal Tumor[J]. Journal of Clinical Oncology, 2008, 26(33): 5352-5359.
[25].Gao J, Tian Y, Li J, et al. Secondary mutations of c-KIT contribute to acquired resistance to imatinib and decrease efficacy of sunitinib in Chinese patients with gastrointestinal stromal tumors[J]. Medical Oncology, 2013, 30(2).
[26].Oppelt P, Hirbe A C, Van Tine B A, et al. Gastrointestinal stromal tumors (GISTs): point mutations matter in management, a review[J]. Journal of gastrointestinal oncology, 2017, 8(3): 466-473.
[27].Corless C L, Schroeder A, Griffith D J, et al. PDGFRA Mutations in Gastrointestinal Stromal Tumors: Frequency, Spectrum and In Vitro Sensitivity to Imatinib[J]. Journal of Clinical Oncology, 2005, 23(23): 5357-5364.
[28].Weisberg E, Wright R D, Jiang J, et al. Effects of PKC412, nilotinib, and imatinib against GIST-associated PDGFRA mutants with differential imatinib sensitivity.[J]. Gastroenterology, 2006, 131(6): 1734-1742.
[29].Florindez J, Trent J C. Low Frequency of Mutation Testing in the United States: An Analysis of 3866 GIST Patients[J]. American Journal of Clinical Oncology, 2020.
[30].Serrano C, Vivancos A, López-Pousa A, et al. Clinical value of next generation sequencing of plasma cell-free DNA in gastrointestinal stromal tumors[J]. BMC cancer, 2020, 20(1): 99.
推荐阅读
- 高血压|世卫组织发布新版高血压用药指南，了解7个要点，有助稳控血压
- 血压|60岁以上血压多少算正常？血压到多少需要吃降压药？为你讲出实情
- 保肝药|没事也要吃保肝药护肝？你以为的“好习惯”，其实正在伤害你的器官……
- 滤泡性淋巴瘤|滤泡性淋巴瘤患者新希望！广东首张奥妥珠单抗药物处方落地
- 阿奇霉素|阿奇霉素，为什么要用3天停4天，不会减弱药效吗？
- 血压|血压超140/90，首选复方降压药！世卫组织高血压新指南
- 药物|吃药不当易伤肝！8种常见药物，正“悄悄”伤害你的肝脏
- 超市|英国男子向超市食品注射不明物体，可能是他自己的血！这？
- 降压药|18岁吃3种降压药，血压仍未达标！医生给出了4个方法，血压正常！
- 最伤肝的五种中药，你还经常吃？每个服中药的人都要注意！